Publication:
EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci

Simple item page
dc.contributor.authorHidalgo-Tenorio, Carmen
dc.contributor.authorSadyrbaeva-Dolgova, Svetlana
dc.contributor.authorEnríquez-Gómez, Andrés
dc.contributor.authorMuñoz, Patricia
dc.contributor.authorPlata-Ciezar, Antonio
dc.contributor.authorMiró, Jose Maria
dc.contributor.authorAlarcón, Arístides de
dc.contributor.authorMartínez-Marcos, Francisco Javier
dc.contributor.authorLoeches, Belén
dc.contributor.authorEschiruela- Vidal, Francesc
dc.contributor.authorVinuesa, David
dc.contributor.authorHerrero, Carmen
dc.contributor.authorBadia-Martí, Cristina
dc.contributor.authorArenas, María del Mar
dc.contributor.authorGarcía-Vázquez, Elisa
dc.contributor.authorArnaiz de las Revillas, Francisco
dc.contributor.authorPasquau, J.
dc.contributor.authorEN-DALBACEN study group
dc.contributor.departmentMedicina
dc.date.accessioned2024-06-26T12:03:36Z
dc.date.available2024-06-26T12:03:36Z
dc.date.issued2023-07-04
dc.description© 2023 The Author(s). Published by Elsevier Ltd. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/. This document is the accepted, version of a Published Work that appeared in final form in International Journal of Antimicrobial Agents . To access the final edited and published work see https://doi.org/10.1016/j.ijantimicag.2023.106918es
dc.description.abstractInfective endocarditis (IE) has high mortality and morbidity and requires long hospital stays to deliver the antibiotic treatment recommended in clinical practice guidelines. The objectives were to analyze the health outcomes of the use of dalbavancin (DBV) in the consolidation treatment of IEs caused by Gram-positive cocci (GPC) and to perform a pharmacoeconomic study. Material and methods: This observational, retrospective, Spanish multicenter study in patients with IE who received DBV as part of antibiotic treatment in consolidation phase and were followed for at least 12 months. The study was approved by the Provincial Committee of the coordinating center. Results: The study included 124 subjects, 70.2% male, with a mean age of 67.4 years and median Charlson index of 4 (IQR:2.5-6). Criteria for definite IE were met by 91.1%. Coagulase-negative staphylococci (38.8%), Staphylococcus aureus (22.6%), Enterococcus faecalis (19.4%), Streptococcus spp. (9.7%) were isolated more frequently, all susceptible to vancomycin. Before DVB administration, 91.2% had undergone surgery, 60.5% had received a second regimen for 24.5 days (16.6-56), and 20.2% a third regimen for 14.5 days (12-19.5). DBV was administered to facilitate discharge in 95.2% of cases. At 12 months, the effectiveness was of 95.9%, there was 0.8% loss to follow-up, 0.8% IE-related death and 3.2% relapse. Adverse events were recorded in 3.2%. The hospital stay was reduced by 14 days and there was a mean saving of 5,548.57€/patient versus conventional treatments. Conclusion: DBV is highly effective, safe, and cost-effective as consolidation therapy in patients with IE by GPC, with few adverse events.es
dc.formatapplication/pdfes
dc.format.extent19es
dc.identifier.citationInternational Journal of Antimicrobial Agents. 2023, 62(3):106918
dc.identifier.doihttps://doi.org/10.1016/j.ijantimicag.2023.106918
dc.identifier.issnPrint: 0924-8579
dc.identifier.issnElectronic: 1872-7913
dc.identifier.urihttp://hdl.handle.net/10201/142693
dc.languageenges
dc.publisherElsevieres
dc.relationSin financiación externa a la Universidades
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0924857923001978?via%3Dihubes
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectEndocarditises
dc.subjectDalbavancines
dc.subjectCost-effectivees
dc.titleEN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive coccies
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
EN-DALBACEN 2.0 Cohort. real-life study of dalbavancin....pdf
Size:
1.23 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos